Related references
Note: Only part of the references are listed.Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Maud Mayoux et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
Anniina Farkkila et al.
NATURE COMMUNICATIONS (2020)
Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
Aleksandra Filipovic et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Xuan Jiang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
3D models in the new era of immune oncology: focus on T cells, CAF and ECM
Francesca Di Modugno et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
Zebin Wang et al.
SCIENTIFIC REPORTS (2019)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2019)
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou et al.
CANCER DISCOVERY (2019)
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
Xuan Jiang et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Ovarian Cancer Immunotherapy: Turning up the Heat
Eleonora Ghisoni et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer
Stephen Shuford et al.
SCIENTIFIC REPORTS (2019)
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
Panagiotis A. Konstantinopoulos et al.
JAMA ONCOLOGY (2019)
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses
Alexandra S. Zimmer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
Stergios Boussios et al.
DIAGNOSTICS (2019)
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028
Andrea Varga et al.
GYNECOLOGIC ONCOLOGY (2019)
Knowing the tumour microenvironment to optimise immunotherapy
M. C. Merlano et al.
ACTA OTORHINOLARYNGOLOGICA ITALICA (2019)
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
Paul G. Baverel et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
Maarten Versteven et al.
FRONTIERS IN IMMUNOLOGY (2018)
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding et al.
CELL REPORTS (2018)
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
Saman Maleki Vareki
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The Peripheral and Intratumoral Immune Cell Landscape in Cancer Patients: A Proxy for Tumor Biology and a Tool for Outcome Prediction
Annette Schnell et al.
BIOMEDICINES (2018)
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Jung-Min Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Update on immune checkpoint inhibitors in gynecological cancers
Valerie Heong et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2017)
Immune Cell Population in Ovarian Tumor Microenvironment
Dong Li Cai et al.
JOURNAL OF CANCER (2017)
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors
M. Ahamadi et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Combenefit: an interactive platform for the analysis and visualization of drug combinations
Giovanni Y. Di Veroli et al.
BIOINFORMATICS (2016)
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
Helene Salmon et al.
IMMUNITY (2016)
Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103+ dendritic cells in late-stage ovarian cancer
Dallas B. Flies et al.
ONCOIMMUNOLOGY (2016)
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity (vol 26, pg 638, 2014)
Miranda L. Broz et al.
CANCER CELL (2014)
Current status of interleukin-10 and regulatory T-cells in cancer
Kristen L. Dennis et al.
CURRENT OPINION IN ONCOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Polyfunctional responses by human T cells result from sequential release of cytokines
Qing Han et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Tumor Necrosis Factor-a Signaling in Macrophages
Narayanan Parameswaran et al.
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION (2010)
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know
YF Shi et al.
CELL RESEARCH (2006)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Macrophage inflammatory protein-1
M Maurer et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2004)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Visualizing priming of virus-specific CD8(+) T cells by infected dendritic cells in vivo
CC Norbury et al.
NATURE IMMUNOLOGY (2002)
Share Paper
